Companies Procept BioRobotics Corp
Procept BioRobotics (PRCT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Procept BioRobotics Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers99th pct.Of 9 peer CEOs
CEO pay, last three years
- $16,783,853FY2025
CEO total pay was $16,783,853 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $304,830 · bonus $1,700,000 · stock awards $7,217,251 · option awards $7,226,599
Executives and directors
Alaleh Nouri · General CounselHisham Shiblaq · CCOReza Zadno · CEOKevin Waters · CFOLarry Wood · CEOAmy Dodrill · Independent DirectorAntal Desai · Independent DirectorDaniel Puckett · Independent DirectorElisabeth Little · Independent DirectorFrederic Moll, M.D · Independent DirectorMary Garrett · Independent DirectorTaylor Harris · Independent DirectorThomas M. Prescott · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Procept BioRobotics Corp in fiscal 2025?
As disclosed, Larry Wood (President & Chief Executive Officer) was the highest-paid executive at Procept BioRobotics Corp in fiscal 2025, with total compensation of $16,783,853.
How does Procept BioRobotics Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Larry Wood's total compensation ranked at the 99th percentile of Procept BioRobotics Corp's disclosed peer group.
What is Procept BioRobotics Corp's CEO-to-median employee pay ratio?
As disclosed, Procept BioRobotics Corp's CEO-to-median employee pay ratio was 132:1.
How did shareholders vote on Procept BioRobotics Corp's executive compensation?
As disclosed, 73.11% of shareholders supported Procept BioRobotics Corp's executive compensation in the latest say-on-pay vote.
How much does Procept BioRobotics Corp spend in total on board compensation for fiscal 2025?
As disclosed, Procept BioRobotics Corp reported total board compensation of $1,163,142 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Larry Wood | $304,830 | $1,700,000 | $7,217,251 | $7,226,599 | $243,864 | $0 | $91,309 | $16,783,853 |
| President & Chief Executive Officer | ||||||||
| Reza Zadno | 471,306 | 0 | 3,790,409 | 1,289,314 | 472,000 | 0 | 743,247 | 6,766,276 |
| Former President & Chief Executive Officer | ||||||||
| Kevin Waters | 502,250 | 0 | 1,480,761 | 503,594 | 256,148 | 0 | 7,500 | 2,750,253 |
| EVP, Chief Financial Officer | ||||||||
| Alaleh Nouri | 471,500 | 0 | 1,177,882 | 400,586 | 220,426 | 0 | 7,500 | 2,277,894 |
| EVP, Chief Legal Officer & Corporate Secretary | ||||||||
| Hisham Shiblaq | 335,958 | — | 1,009,596 | 343,372 | 0 | 0 | 275,814 | 1,964,740 |
| Former EVP, Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Larry Wood | $16,783,853 | — | — | — |
| Reza Zadno | 6,766,276 | 6,521,876 | 6,088,813 | ↑ +244,400 |
| Kevin Waters | 2,750,253 | 2,187,988 | 2,665,306 | ↑ +562,265 |
| Alaleh Nouri | 2,277,894 | 2,653,751 | 2,193,961 | ↓ −375,857 |
| Hisham Shiblaq | 1,964,740 | 3,587,208 | 2,631,135 | ↓ −1,622,468 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract and retain our NEOs, align the interests of our NEOs with the interests of our stockholders, and incentivize and reward performance that contributes to our short-term and long-term success. Generally, this is accomplished by tying a substantial portion of our NEOs total compensation to the achievement of meaningful pre-set, objective financial or operating goals, such as in our annual incentive program, or to our stock price, via our long-term incentive program, making it variable and thus putting it at risk.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alaleh Nouri | OPTION | 2025-03-03 | — | — | 11,445 | — | $400,586 |
| Larry Wood | RSU | 2025-09-02 | — | — | 182,392 | — | 7,217,251 |
| Larry Wood | OPTION | 2025-09-02 | — | — | 319,618 | — | 7,226,599 |
| Reza Zadno | OPTION | 2025-03-03 | — | — | 36,831 | — | 1,289,314 |
| Hisham Shiblaq | OPTION | 2025-03-03 | — | — | 9,810 | — | 343,372 |
| Kevin Waters | OPTION | 2025-03-03 | — | — | 14,388 | — | 503,594 |
| Hisham Shiblaq | PSU | 2025-03-03 | 3,471 | 5,553 | 11,107 | 9,718 | 1,009,596 |
| Reza Zadno | PSU | 2025-03-03 | 13,031 | 20,849 | 41,699 | 36,486 | 3,790,409 |
| Kevin Waters | PSU | 2025-03-03 | 5,091 | 8,145 | 16,290 | 14,254 | 1,480,761 |
| Alaleh Nouri | PSU | 2025-03-03 | 4,049 | 6,479 | 12,958 | 11,338 | 1,177,882 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alaleh Nouri | $0 | $1,177,882 | $400,586 | 74.6% |
| Larry Wood | 7,217,251 | 0 | 7,226,599 | 0.0% |
| Reza Zadno | 0 | 3,790,409 | 1,289,314 | 74.6% |
| Hisham Shiblaq | 0 | 1,009,596 | 343,372 | 74.6% |
| Kevin Waters | 0 | 1,480,761 | 503,594 | 74.6% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alaleh Nouri | Option | 431 | 34.99 | — |
| Larry Wood | Option | 734 | 51.08 | — |
| Alaleh Nouri | RSU | 851 | — | 26,772 |
| Kevin Waters | Option | 1,002 | 34.99 | — |
| Alaleh Nouri | PSU | 1,620 | — | 50,965 |
| Kevin Waters | RSU | 1,979 | — | 62,259 |
| Kevin Waters | PSU | 2,036 | — | 64,053 |
| Alaleh Nouri | RSU | 2,145 | — | 67,482 |
| Kevin Waters | RSU | 2,697 | — | 84,848 |
| Reza Zadno | Option | 4,974 | 34.99 | — |
| Reza Zadno | PSU | 5,212 | — | 163,970 |
| Kevin Waters | Option | 6,505 | 47.17 | — |
| Kevin Waters | PSU | 6,637 | — | 208,800 |
| Alaleh Nouri | Option | 8,972 | 47.17 | — |
| Alaleh Nouri | PSU | 9,155 | — | 288,016 |
| Reza Zadno | RSU | 9,828 | — | 309,189 |
| Kevin Waters | RSU | 9,957 | — | 313,247 |
| Alaleh Nouri | RSU | 10,526 | — | 331,148 |
| Alaleh Nouri | Option | 11,934 | 37.02 | — |
| Alaleh Nouri | RSU | 12,958 | — | 407,659 |
| Kevin Waters | RSU | 13,158 | — | 413,951 |
| Alaleh Nouri | RSU | 13,734 | — | 432,072 |
| Kevin Waters | Option | 14,917 | 37.02 | — |
| Kevin Waters | RSU | 16,290 | — | 512,483 |
| Reza Zadno | Option | 23,800 | 47.17 | — |
| Reza Zadno | PSU | 24,287 | — | 764,069 |
| Reza Zadno | RSU | 32,895 | — | 1,034,877 |
| Reza Zadno | RSU | 36,432 | — | 1,146,151 |
| Reza Zadno | Option | 37,292 | 37.02 | — |
| Larry Wood | RSU | 182,392 | — | 5,738,052 |
| Larry Wood | Option | 319,618 | 39.57 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas M. PrescottIndependent · Board Chair · Audit | $100,376 | $98,786 | $98,690 | — | $0 | $297,852 |
| Taylor HarrisIndependent · Audit (Chair) | 68,544 | 98,786 | 98,690 | — | 0 | 266,020 |
| Elisabeth LittleIndependent · Compensation (Chair) · Nominating/Governance | 68,544 | 98,786 | 98,690 | — | 0 | 266,020 |
| Amy DodrillIndependent · Audit · Compensation | 66,044 | 98,786 | 98,690 | — | 0 | 263,520 |
| Antal DesaiIndependent · Compensation · Nominating/Governance | 61,044 | 98,786 | 98,690 | — | 0 | 258,520 |
| Mary GarrettIndependent · Nominating/Governance (Chair) | 58,544 | 98,786 | 98,690 | — | 0 | 256,020 |
| Frederic Moll, M.DIndependent | 48,544 | 98,786 | 98,690 | — | 0 | 246,020 |
| Larry L. WoodEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Daniel PuckettIndependent · Audit · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $180,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $471,640 |
| Equity awards (grant-date value) | $691,502 |
| All other compensation | $0 |
| Total cost of the board | $1,163,142 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Procept BioRobotics as a peer
Companies that benchmark against PRCT
9 companies name PRCT as a compensation peer
The list of companies that name PRCT as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
INSP Inspire Medical SystemsRXST RxSightKIDS OrthoPediatricsPEN PenumbraCERT CertaraSILK Silk Road MedicalFNA Paragon 28NVRO NevroRVNC Revance Therapeutics
Peer reciprocity
The companies Procept BioRobotics Corp names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Procept BioRobotics Corp | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | Silk Road Medical | 2023 | Chas McKhann | 105,871 | 13,123,059 | 0 | 93,275 | 13,423,834 |
| 3 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 4 | Revance Therapeutics | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 5 | Inspire Medical Systems | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 6 | Certara | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 7 | RxSight | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 8 | OrthoPediatrics | 2025 | David Bailey | 550,000 | 2,445,200 | 0 | 322,281 | 3,331,481 |
| 9 | Paragon 28 | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 10 | Penumbra | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Procept BioRobotics Corp | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Certara | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| Inspire Medical Systems | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Nevro | 53.7% | not disclosed | No | Aon |
| OrthoPediatrics | 78.2% | RSU 100 | not disclosed | NFP Compensation Consulting |
| Paragon 28 | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Penumbra | not disclosed | not disclosed | No | Compensia |
| Revance Therapeutics | 96.8% | PSU 100 | No | FW Cook |
| RxSight | 32.18% | Option 100 | not disclosed | Aon |
| Silk Road Medical | not disclosed | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 26,984,867 | 9,924,704 | 45,735 | 73.11% | Passed |
| 2025 | 2025-06-10 | 40,260,405 | 1,906,382 | 30,232 | 95.48% | Passed |
| 2024 | 2024-06-04 | 37,459,317 | 1,254,400 | 115,480 | 96.76% | Passed |
| 2022 | 2022-06-07 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 73.11%a |
| 2025 | 2025-06-10 | 95.48%b |
| 2024 | 2024-06-04 | 96.76%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker-non-votes will not be considered votes cast on Proposal No. 3;”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 132 : 1 |
|---|---|
| CEO total compensation | $23,550,129 |
| Median employee compensation | $178,612 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Barry L. Templin | EVP, Chief Technology Officer | 2026-06-08 | D | 358 | $28 | $10,195 | Common | Form 4 ↗ |
| Alaleh Nouri | EVP, CLO, Corp. SEC. | 2026-06-08 | D | 285 | 28 | 8,117 | Common | Form 4 ↗ |
| Kevin Waters | EVP, CFO | 2026-06-08 | D | 357 | 28 | 10,167 | Common | Form 4 ↗ |
| Frederic H. Moll | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Elisabeth Little | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Antal Desai | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederic H. Moll | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy Dodrill | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Taylor Harris | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Puckett | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Elisabeth Little | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas M. Prescott | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Taylor Harris | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Mary Garrett | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy Dodrill | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Antal Desai | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Daniel Puckett | Director | 2026-06-09 | A | 5,853 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas M. Prescott | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Mary Garrett | Director | 2026-06-09 | A | 3,315 | 0 | 0 | Common | Form 4 ↗ |
| Larry L. Wood | Director | 2026-08-07 | A | 23,900 | 21 | 498,315 | Common | Form 4 ↗ |
| Barry L. Templin | EVP, Chief Technology Officer | 2026-08-13 | A | 26,246 | 0 | 0 | Common | Form 4 ↗ |
| Alaleh Nouri | EVP, CLO, Corp. SEC. | 2026-08-13 | A | 31,773 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alaleh Nouri | EVP, CLO, Corp. SEC. | 2026-08-13 | A | 22,965 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Waters | EVP, CFO | 2026-08-13 | A | 29,527 | 0 | 0 | Common | Form 4 ↗ |
| Barry L. Templin | EVP, Chief Technology Officer | 2026-08-13 | A | 36,312 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Waters | EVP, CFO | 2026-08-13 | A | 40,851 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pooja Sharma | Chief Strat/Marketing Officer | 2026-08-13 | A | 32,681 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Pooja Sharma | Chief Strat/Marketing Officer | 2026-08-13 | A | 23,622 | 0 | 0 | Common | Form 4 ↗ |
| Barry L. Templin | EVP, Chief Technology Officer | 2026-09-09 | D | 373 | 21 | 7,815 | Common | Form 4 ↗ |
| Kevin Waters | EVP, CFO | 2026-09-09 | D | 373 | 21 | 7,815 | Common | Form 4 ↗ |
| Alaleh Nouri | EVP, CLO, Corp. SEC. | 2026-09-09 | D | 297 | 21 | 6,223 | Common | Form 4 ↗ |
| Michael Mack | Director | 2026-10-02 | A | 7,727 | 0 | 0 | Common | Form 4 ↗ |
| Michael Mack | Director | 2026-10-02 | A | 12,191 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (75 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Larry Wood. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 35. As printed: 16,783,853. View filing ↗
- Section 01, Reza Zadno. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 6,766,276. View filing ↗
- Section 01, Kevin Waters. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 2,750,253. View filing ↗
- Section 01, Alaleh Nouri. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 2,277,894. View filing ↗
- Section 01, Hisham Shiblaq. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 1,964,740. View filing ↗
- Section 03, Alaleh Nouri OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Larry Wood RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Larry Wood OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Reza Zadno OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hisham Shiblaq OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Waters OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hisham Shiblaq PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Reza Zadno PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Waters PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alaleh Nouri PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: 132 : 1. View filing ↗
- Section 08, Thomas M. Prescott. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 297,852. View filing ↗
- Section 08, Taylor Harris. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 266,020. View filing ↗
- Section 08, Elisabeth Little. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 266,020. View filing ↗
- Section 08, Amy Dodrill. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 263,520. View filing ↗
- Section 08, Antal Desai. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 258,520. View filing ↗
- Section 08, Mary Garrett. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 256,020. View filing ↗
- Section 08, Frederic Moll, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 246,020. View filing ↗
- Section 08, Larry L. Wood. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Daniel Puckett. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Barry L. Templin 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alaleh Nouri 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Waters 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederic H. Moll 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elisabeth Little 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antal Desai 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederic H. Moll 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy Dodrill 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Taylor Harris 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Puckett 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elisabeth Little 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas M. Prescott 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Taylor Harris 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Garrett 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy Dodrill 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antal Desai 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Puckett 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas M. Prescott 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Garrett 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Larry L. Wood 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry L. Templin 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alaleh Nouri 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alaleh Nouri 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Waters 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry L. Templin 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Waters 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pooja Sharma 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pooja Sharma 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry L. Templin 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Waters 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alaleh Nouri 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Mack 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Mack 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 73.11% (votes for as printed: 26,984,867). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 95.48% (votes for as printed: 40,260,405). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-05. Item 5.07 · say-on-pay result. As reported: 96.76% (votes for as printed: 37,459,317). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 471,640 + equity 691,502 + all other 0 = 1,163,142, summed across the director compensation table rows.
- Procept BioRobotics Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics Corp's own proxy. As printed: 16,783,853. View filing ↗
- Silk Road Medical, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. View filing ↗
- Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
- Revance Therapeutics, Section 10b CEO total. DEF 14A, filed 2024-03-21. CEO total compensation as printed in Revance Therapeutics's own proxy. As printed: 10,068,915. View filing ↗
- Inspire Medical Systems, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems's own proxy. As printed: 7,711,784. View filing ↗
- Certara, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Certara's own proxy. As printed: 6,491,387. View filing ↗
- RxSight, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. View filing ↗
- OrthoPediatrics, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in OrthoPediatrics's own proxy. As printed: 3,331,481. View filing ↗
- Paragon 28, Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28's own proxy. As printed: 3,232,420. View filing ↗
- Penumbra, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra's own proxy. As printed: 851,621. View filing ↗
- Section 10a, RxSight reciprocity. DEF 14A. RxSight names Procept BioRobotics Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗